je.st
news
Tag: cubist
Layoffs at Cubist come amid a steady flow of senior execs out of Merck
2015-03-07 10:48:14| Biotech - Topix.net
The layoffs announced in Lexington this week by the new owner of Cubist Pharmaceuticals come amid an outflow of high-ranking executives from the antibiotics company seeking new positions, according to local job placement experts. In recent days, local staffing firms who work in the life science industry confirmed that there have been a slew of calls from Cubist employees at all levels looking for new jobs in the three months since Merck & Co.
Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubists 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020
2015-02-23 23:03:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced the results of its tender offer (the Convertible Notes Tender Offer) pursuant to which each holder of Cubists 2.50% Convertible Senior Notes due 2017 (the 2017 Convertible Notes), 1.125% Convertible Senior Notes due 2018 (the 2018 Convertible Notes) and 1.875% Convertible Senior Notes due 2020 (the 2020 Convertible Notes and together with th Language: English Contact: MerckMedia:Lainie Keller, (908) 236-5036Steve Cragle, (908) 740-1801orInvestor:Joe Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubists 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020
2015-01-22 21:29:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced that, in connection with the completion of the acquisition of Cubist by Merck, Cubist has commenced a tender offer (the Convertible Notes Tender Offer) to repurchase, at the option of each holder, any and all of its outstanding 2.50% Convertible Senior Notes due 2017 (the 2017 Convertible Notes), 1.125% Convertible Senior Notes due 2018 (the
Merck Completes Tender Offer to Acquire Cubist
2015-01-21 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) at a purchase price of $102.00 per share. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orSteve Cragle, 908-740-1801orInvestor:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: offer
acquire
tender
completes
Approval of new antibiotic by Cubist to help in $100 trillion global fight
2014-12-22 17:40:08| Biotech - Topix.net
Friday's FDA approval of the latest new antibiotic by Cubist Pharmaceuticals is a step toward combating a problem estimated to kill 10 million people and cost $100 trillion globally by 2050. Late Friday, U.S. regulators gave the nod to Zerbaxa, formerly known by the generic name of ceftolozane/tazobactam, for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections caused by certain so-called Gram-negative bacteria, typically considered among the hardest to kill.
Tags: global
fight
approval
antibiotic